Clinical Trials Logo

Filter by:
NCT ID: NCT03779009 Recruiting - Colon Cancer Clinical Trials

Minimally INvasive Colon Cancer Surgery Through IMmunomics and Optical Mapping of the Sentinel Lymph Node.

MINIMAL
Start date: March 1, 2018
Phase: N/A
Study type: Interventional

The project investigates the feasibility of laparoscopic fluorescent imaging for the intraoperative detection of the sentinel lymph node (SLN) in colon cancer patients. In addition, the topology of immunological and microenvironmental changes in normal and invaded lymph nodes (LN's) will be correlated to the LN location (anatomical mapping).

NCT ID: NCT03774199 Recruiting - Clinical trials for Pulse Oximeter Calibration

NightOwl Pulse Oximeter Calibration Study

NPOCS
Start date: December 14, 2018
Phase: N/A
Study type: Interventional

Calibration of a software module that computes SpO2 based on photoplethysmography (PPG) traces acquired by a reflectance-based pulse oximeter which can be placed on the index finger or the forehead. The study is designed in accordance with Medical electrical equipment - Part 2-61: Particular requirements for basic safety and essential performance of pulse oximeter equipment (ISO 80601- 2-61:2011)

NCT ID: NCT03773965 Recruiting - Clinical trials for Juvenile Idiopathic Arthritis

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

JUVE-X
Start date: April 5, 2019
Phase: Phase 3
Study type: Interventional

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

NCT ID: NCT03768063 Recruiting - Cancer Clinical Trials

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

IMbrella B
Start date: February 28, 2019
Phase: Phase 3
Study type: Interventional

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.

NCT ID: NCT03767569 Recruiting - PCOS Clinical Trials

Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients

Start date: September 1, 2018
Phase: Phase 3
Study type: Interventional

A randomized controlled trial to evaluate whether pretreatment with myo-inositol can lower testosterone levels and improve clinical outcomes in hyperandrogenic PCOS patients undergoing ART

NCT ID: NCT03764124 Recruiting - Clinical trials for Kidney Transplantation

Observation Study for Prediction of Allograft Survival and Impact of Imaging in Kidney Transplant Recipients.

Start date: January 1, 2007
Phase:
Study type: Observational

To further develop personalized medicine in kidney transplantation and improve transplant patient outcomes, attention has been given to define early surrogate endpoints that might aid therapeutic interventions, and help clinical decision-making. To adequately predict transplant patients' individual risks of allograft loss and patients' complications, this would require a complex integration of data, including: donor data, recipient characteristics, transplant characteristics, biopsies results, immunosuppressive regimen, allograft infections, acute kidney injuries, recipient immune profiles, protocol and per cause biopsies and imaging (PET/CT imaging). This project aims: 1. Assessed the usefulness of 18F-FDG PET/CT imaging in kidney transplantation recipients presenting with suspected acute rejection who underwent a transplant needle biopsy; 2. To develop a prognostic risk score to predict kidney allograft survival; 3. To evaluate the impact of corticoids withdrawal on long term outcomes (risk of rejection and impact on bone mineral density); 4. Evaluate the type and the frequencies of complications in our kidney transplant population

NCT ID: NCT03761108 Recruiting - Multiple Myeloma Clinical Trials

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

LINKER-MM1
Start date: January 23, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: - Side effects that may be experienced by people receiving REGN5458 - How REGN5458 works in the body - How much REGN5458 is present in the blood - How REGN5458 may work to treat cancer

NCT ID: NCT03757793 Recruiting - Clinical trials for Breast Reconstruction

Near-infrared Spectroscopy for Monitoring Tissue Oxygenation in Breast Reconstruction

Start date: September 28, 2018
Phase:
Study type: Observational

The study will evaluate the use of near infrared spectrometry (NIRS)in detecting early microvascular complications in deep inferior epigastric artery perforator (DIEP)-flap(s).

NCT ID: NCT03755856 Recruiting - Clinical trials for Acute Myeloid Leukemia

Long-term Outcomes for Acute Myeloid Leukemia Patients

1621-QLG-LG
Start date: May 16, 2019
Phase:
Study type: Observational

This international observational study aims at examining the patterns of health-related quality of life differences between long-term acute myeloid leukemia patients and their healthy peers from the general population.

NCT ID: NCT03755388 Recruiting - Knee Injuries Clinical Trials

Clinical Trial of an MRI Based Patient Specific Focal Knee Resurfacing Implant

Episealer2
Start date: September 20, 2018
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the efficacy, safety and performance of the Episealer® device in a sample size of 30 patients and on the long term (10 years follow-up).